flavokavain B, flavokavin B, flavokawain B
| Name | Flavokawain B | ||
| PubChem CID | 5356121 | ||
| Molecular Weight | 284.31g/mol | ||
| Synonyms |
flavokavain B, flavokavin B, flavokawain B |
||
| Formula | C₁₇H₁₆O₄ | ||
| SMILES | COC1=CC(=C(C(=C1)OC)C(=O)C=CC2=CC=CC=C2)O | ||
| InChI | 1S/C17H16O4/c1-20-13-10-15(19)17(16(11-13)21-2)14(18)9-8-12-6-4-3-5-7-12/h3-11,19H,1-2H3/b9-8+ | ||
| InChIKey | QKQLSQLKXBHUSO-CMDGGOBGSA-N | ||
| CAS Number | 1775-97-9 | ||
| ChEMBL ID | CHEMBL104255 | ||
| ChEBI ID | CHEBI:65899 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | KaWaHuJiao | ||
| Use Part | Root and rhizome | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Piperales
-->Family: Piperaceae
-->Genus: Piper
-->Species: Piper methysticum
|
||
| Pair Name | Flavokawain B, Daunorubicin | |||
| Partner Name | Daunorubicin | |||
| Disease Info | [ICD-11: 2B33.4] | Leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Activity | NFKB1 | hsa4790 |
| In Vitro Model | HL-60 | Adult acute myeloid leukemia | Homo sapiens (Human) | CVCL_0002 |
| K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 | |
| MOLT-4 | Adult T acute lymphoblastic leukemia | Homo sapiens (Human) | CVCL_0013 | |
| Result | A combination treatment of DNR and FKB may improve the anticancer effects of DNR in DNR-resistant acute myeloid leukemia. | |||
| Pair Name | Flavokawain B, Bortezomib | |||
| Partner Name | Bortezomib | |||
| Disease Info | [ICD-11: 2C82.0] | Prostate cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | SKP2 | hsa6502 |
| Up-regulation | Expression | PSMD9 | hsa5715 | |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | cleavage | PARP1 | hsa142 | |
| In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
| PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 | |
| LNCaP C4-2B | Prostate carcinoma | Homo sapiens (Human) | CVCL_4784 | |
| Result | These findings provide a rationale for further investigating combination of FKB and Bortezomib for treatment of RB deficient, castration-resistant prostate cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | The Combination of Flavokawain B and Daunorubicin Induces Apoptosis in Human Myeloid Leukemic Cells by Modifying NF-κB. Anticancer Res. 2018 May;38(5):2771-2778. doi: 10.21873/anticanres.12520. | Click |
| 2 | Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. Cell Commun Signal. 2019 Mar 18;17(1):25. doi: 10.1186/s12964-019-0338-2. | Click |
